ClinicalTrials.gg
Drug

Savolitinib clinical trials

Also written HMPL-504, Volitinib and AZD6094.

studies test it
39
open now
3
in phase 3
6
first study started
2012

How each study uses savolitinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the savolitinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Savolitinib
26
AZD6094, HMPL-504, volitinib
2
Orpathys
2

Development codes

HMPL-504
11
AZD6094
10

Other names

Volitinib
11

Studies by the year they started

39 studies that test it; most in 2019 (6)

Studies that test savolitinib, by start year
YearStudies
20121
20132
20142
20152
20164
20174
20182
20196
20202
20215
20223
20234
20242

By phase

A phase 1/2 study counts in both.

Phase 1
18
Phase 2
17
Phase 3
6

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 25 · Other 14

AstraZeneca (15) · Hutchison Medipharma Limited (9) · National Cancer Institute (NCI) (3) · Samsung Medical Center (3) · Hutchmed (1) · Canadian Cancer Trials Group (1) · Assistance Publique Hopitaux De Marseille (1) · Guangdong Association of Clinical Trials (1)

Often tested with

Tested in the same studies.

Durvalumab (2) · Tremelimumab (2) · Crizotinib (2) · Docetaxel (2) · Osimertinib (1) · Adavosertib (1) · Darolutamide (1) · Ocifisertib fumarate (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 4

Studies that test savolitinib.

Studies

Open first, then newest update. How each study uses savolitinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 39

See all 39 studies that test savolitinib →

Given beside what is tested · 4 — savolitinib is usual care or a partner of the new treatment

Codes

What other systems call savolitinib · ClinicalTrials.gg INT000122

  • MeSH (NLM) C0005932591-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazineConfirmed NLM, Wikidata
  • UNII (FDA) 2A2DA6857RSAVOLITINIBConfirmed FDA, NLM, Wikidata
  • Wikidata Q27254463savolitinibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C104732SavolitinibOne source FDA
  • DrugBank DB12048One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.